Search research articles
Contact Us
Filters
Showing results (261-270 of 275) with videos related to
Page
of 28
Sort By:
The New England Journal of Medicine
|
August 28, 2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
, Louise Bowman, Marion Mafham, et al.
Haematologica
|
October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion
Constantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Journal of Neuroinflammation
|
April 1, 2017
Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment
Sanjay R Mehta, Josué Pérez-Santiago, Todd Hulgan, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
American Journal of Hematology
|
August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies
Tadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Nature
|
February 1, 2019
Secondary organic aerosol reduced by mixture of atmospheric vapours
Gordon McFiggans, Thomas F Mentel, Jürgen Wildt, et al.
The Lancet. Oncology
|
April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Lancet (London, England)
|
December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles, John Francis Seymour, Fritz Offner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy, John F Seymour, Pierre Feugier, et al.
EMBO Reports
|
August 24, 2022
Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spike
Diego Cantoni, Matthew J Murray, Mphatso D Kalemera, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 275) with videos related to
Sort By:
Page
of 28
The New England Journal of Medicine
|
August 28, 2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
, Louise Bowman, Marion Mafham, et al.
Haematologica
|
October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion
Constantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
Journal of Neuroinflammation
|
April 1, 2017
Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment
Sanjay R Mehta, Josué Pérez-Santiago, Todd Hulgan, et al.
The Lancet. Haematology
|
July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
American Journal of Hematology
|
August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies
Tadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Nature
|
February 1, 2019
Secondary organic aerosol reduced by mixture of atmospheric vapours
Gordon McFiggans, Thomas F Mentel, Jürgen Wildt, et al.
The Lancet. Oncology
|
April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Lancet (London, England)
|
December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles, John Francis Seymour, Fritz Offner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy, John F Seymour, Pierre Feugier, et al.
EMBO Reports
|
August 24, 2022
Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spike
Diego Cantoni, Matthew J Murray, Mphatso D Kalemera, et al.
Page
of 28